Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma

Abstract

No validated biomarkers exist for treatment selection in dedifferentiated liposarcoma (DDLPS). Although murine double minute 2 (<i>MDM2</i>) is currently used for diagnosis, the clinical relevance of <i>MDM2</i> amplification has yet to be fully assessed. This study found that <i>MDM2</i> amplification follows a predictable distribution in DDLPS and correlates with clinical and biological outcomes. These data suggests that <i>MDM2</i> amplification may be a useful biomarker in DDLPS.